NEW YORK, Sept. 6 – Gene Logic has licensed a pair of its technology platforms and a set of gene targets to a business unit of Belgian drug company UCB Pharma, the companies said on Thursday.
Under the deal, which broadens an existing collaboration inked in 1999, UCB Research, of Cambridge, Mass., will gain access to the BioExpress Module of Gene Logic’s GeneExpress suite plus the Genesis Enterprise System, according to a statement.
UCB also has bought an exclusive license to allergy and asthma gene targets and gene-expression data culled form the firms’ original deal, they said.
Financial terms of this recent collaboration were not disclosed. However, the companies said that Gaithersburg, Md.-based Gene Logic “will recognize multi-year revenue” from the two new licensing agreements, as well as “one time revenue” for the gene-targets and -expression data.